A VEGFR targeting peptide-drug conjugate (PDC) suppresses tumor angiogenesis in a TACE model for hepatocellular carcinoma therapy
2022 · Cell Death Discovery · 23 citations
https://doi.org/10.1038/s41420-022-01198-9
C
Chongtu Yang
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
68
Papers
1.1K
Citations
17
h-index
33
i10-index
Chongtu Yang is an academic researcher from Sichuan University. The author has contributed to research in topics: Liver Disease Diagnosis and Treatment & Liver Disease and Transplantation & Hepatocellular Carcinoma Treatment and Prognosis. The author has an h-index of 17, co-authored 58 publications.
ORCID: 0000-0001-5384-9778Papers by this author
worksLate combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination
2022 · BMC Cancer · 20 citations
https://doi.org/10.1186/s12885-022-09451-1
<scp>MRI</scp> ‐Based Topology Deep Learning Model for Noninvasive Prediction of Microvascular Invasion and Assisting Prognostic Stratification in <scp>HCC</scp>
2025 · Liver International · 13 citations
https://doi.org/10.1111/liv.16205
Dynamic changes in liver function after transjugular intrahepatic portosystemic shunt in patients with cirrhosis
2022 · Journal of interventional medicine · 5 citations
https://doi.org/10.1016/j.jimed.2022.09.001
MRI-based prediction of the need for wide resection margins in patients with single hepatocellular carcinoma
2024 · European Radiology · 4 citations
https://doi.org/10.1007/s00330-024-11043-5
Transjugular intrahepatic portosystemic shunt for the treatment of hepatic sinusoidal obstruction syndrome caused by pyrrolizidine alkaloids: A multicenter retrospective study
2023 · Heliyon · 3 citations
https://doi.org/10.1016/j.heliyon.2023.e23455
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat